The Synthetic Retinoid Fenretinide Lowers Plasma Insulin-like Growth Factor I Levels in Breast Cancer Patients1

Abstract

We studied the effect of fenretinide [/V-(4-hydroxyphenyl)retinamide (4-HPR)], a synthetic analogue of retinoic acid, on plasma insulin-like growth factor I (IGF-I) levels in a consecutive cohort of stage I breast cancer patients belonging to a randomized phase III trial of breast cancer chemoprevention. Thirty-two women receiving 4-HPR 200 mg/daily and 28… (More)

Topics

3 Figures and Tables

Slides referencing similar topics